Bispecific Her2 × cotinine antibody in combination with cotinine-(histidine)2-iodine for the pre-targeting of Her2-positive breast cancer xenografts.

CONCLUSIONS: With these findings, we conclude that the tandem scFv Fc fusion protein and cotinine hapten system have the potential to be applied in PRIT. PMID: 24292501 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24292501?dopt=Abstract

Source: Clinical Breast Cancer - December 1, 2013 Category: Cancer & Oncology Authors: Yoon S, Kim YH, Kang SH, Kim SK, Lee HK, Kim H, Chung J, Kim IH Tags: J Cancer Res Clin Oncol Source Type: research